Robert Feldman, MD
Geriatric Medicine · Laguna Hills, CANPI 1194805416
Payments from drug & device makers
Across 2,122 payments — averaging $900.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$846K
- Amgen$523K
- Eli Lilly$345K
- Biogen$113K
- Merck$57K
- Lilly USA, LLC$13K
- plus $13K from 13 others
Across 3 payments — averaging $290.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$871
What the payments were for
- Consulting fees$13,7251%
- Speaking & faculty fees$904,02178%
- Travel & lodging$207,93618%
- Food & beverage$34,3213%
- Education$4700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 802 | $846,368 |
| Amgen | 1,101 | $523,356 |
| Eli Lilly | 13 | $344,696 |
| Biogen | 14 | $112,880 |
| Merck | 65 | $56,687 |
| Lilly USA, LLC | 49 | $12,885 |
| Johnson & Johnson | 60 | $9,415 |
| Acadia Pharmaceuticals Inc | 1 | $1,600 |
| Xeris Pharmaceuticals, Inc. | 2 | $1,463 |
| Radius Health, Inc. | 4 | $215 |
| Novartis | 3 | $56 |
| Eisai Inc. | 1 | $49 |
| UCB, Inc. | 1 | $29 |
| Pfizer | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,909,799 in reported general payments places this provider in the 95th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 107 | $87,056 |
| EliquisApixaban | 63 | $59,099 |
| ProliaDenosumab | 36 | $58,982 |
| JanuviaSitagliptin Phosphate | 39 | $38,135 |
| TymlosAbaloparatide | 11 | $31,364 |
| EntrestoSacubitril/Valsartan | 19 | $21,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,253 |
| MyrbetriqMirabegron | 17 | $14,977 |
| Repatha SureclickEvolocumab | 13 | $10,340 |
| Rivastigmine | 22 | $9,020 |
| Risedronate Sodium | 95 | $7,759 |
| Metoprolol Succinate | 449 | $7,600 |
| Pantoprazole Sodium | 432 | $5,776 |
| Memantine Hcl | 158 | $5,562 |
| Rosuvastatin Calcium | 391 | $5,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $9,415 | $87,056107 claims |
| PfizerEliquis | $23 | $59,09963 claims |
| AmgenProlia | $523,356 | $58,98236 claims |
| MerckJanuvia | $56,687 | $38,13539 claims |
| Radius Health, Inc.Tymlos | $215 | $31,36411 claims |
| NovartisEntresto | $56 | $21,61019 claims |
| GSKTrelegy Ellipta | $846,368 | $21,25325 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $14,97717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Laguna Hills
- Jorge RiveroLaguna Hills$4K
- Paul AisenSan Diego$15.7M
- Kanagaratnam SivalingamLancaster$2.4M
- Wayne ChenLos Angeles$2M
- Isabel PereiraFountain Valley$1.2M
- Timothy ParenteauOakland$221K
- Oscar ChienSan Gabriel$208K
- Anna ChangSan Francisco$170K
- Anders NybergSan Diego$163K
- Christopher SalemIrvine$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.